Supplemental Figure 2 from AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol

Detlefsen, Andrea J.; Mesaros, Clementina A.; Duan, Ling; Penning, Trevor M.

doi:10.1158/2767-9764.24162494.v1

Supplemental Figure 2 from AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol

journal contribution

posted on 2023-09-19, 14:20 authored by Andrea J. Detlefsen, Clementina A. Mesaros, Ling Duan, Trevor M. Penning

Supplemental Figure 2 shows standard curves generated for hydroxyandrogens using SIC-LC-MS/MS.

Funding

HHS | NIH | National Institute of Environmental Health Sciences (NIEHS)

HHS | NIH | National Institute of General Medical Sciences (NIGMS)

History

ARTICLE ABSTRACT

We show that reservoirs of DHEA-S that remain after ARSI treatment are converted into T in primary and metastatic prostate cancer cells in amounts sufficient to stimulate cell growth. Pharmacologic and genetic approaches demonstrate that AKR1C3 is required for these effects. Furthermore, the route to T proceeds through 5-Adiol. We propose that this is a mechanism of ARSI drug resistance.